OFF-RAMP Feasibility Trial

STUDY BASICS

Are you currently using a GLP-1 for weight loss? You may be eligible for a research study on the acceptability of different treatment strategies to help maintain weight loss. Study participation includes 3 in-person study visits. Compensation is provided.

STUDY PURPOSE

The purpose of this research is to compare weight loss among 3 groups:

• people who stay on a GLP-1 drug at full strength (Group 1)
• people who have their dose tapered to every other week, meaning slowly decreasing the dose and frequency of the full prescription you are currently taking (Group 2)
• people who go off their GLP-1 and instead take an alternative weight loss drug or combination of drugs (i.e., phentermine-topiramate, phentermine alone, or in some cases bupropion, or bupropion & naltrexone if you cannot take phentermine/topiramate) These are not GLP-1 medications. (Group 3)

We want to see if the second and third options are effective at weight loss maintenance. 

COULD THIS STUDY BE RIGHT FOR YOU?

• At least 18 years old with a body-mass index greater than or equal to 30
• Currently using either Wegovy (at least 1.7mg) or Zepbound (at least 10mg)
• Have lost 5% or more when compared to your baseline body weight
• Have not been diagnosed with type 2 diabetes
• Must not be pregnant, or seeking to become pregnant

WHAT PARTICIPANTS CAN EXPECT

• Three in person study visits
• Monthly check-in visits by phone
• Randomized to one of three groups for up to 12 months:
  1. Stay on a higher intensity GLP-1 based regimen
  2. Gradually decrease the dose of your GLP-1 to a lower dose and inject less frequently
  3. Gradually decrease the dose of your GLP-1 and then switch to daily oral treatment strategy